Centre de Recherche, Centre Hospitalier de l'Université de Montréal, 1560 Sherbrooke East, Montréal, QC H2L 4M1, Canada.
Nat Rev Urol. 2013 Sep;10(9):522-8. doi: 10.1038/nrurol.2013.137. Epub 2013 Jun 25.
Over the past few years, we have developed an increased understanding of the molecular mechanisms that underlie prostate cancer progression and castration resistance and expanded our repertoire of therapeutic options for castration-resistant prostate cancer (CRPC). Four new agents (cabazitaxel, abiraterone acetate, enzalutamide, and radium-233) have been shown to prolong overall survival in patients with CRPC in the postchemotherapy setting. Targeting the androgen receptor pathway continues to have an important role in the treatment of CRPC, with abiraterone acetate and enzalutamide being the most exciting developments. Cabazitaxel is now considered the standard-of-care second-line chemotherapy for men with metastatic CRPC (mCRPC). Bone-targeted therapy is an active area of research, with denosumab being the first bone-targeted agent able to significantly delay the appearance of bone metastases in patients with CRPC and radium-223 being the first radiopharmaceutical agent to improve survival in patients with mCRPC.
在过去的几年中，我们对前列腺癌进展和去势抵抗的分子机制有了更深入的了解，并扩大了我们治疗去势抵抗性前列腺癌 (CRPC) 的治疗选择。四项新的药物（卡巴他赛、醋酸阿比特龙、恩扎鲁胺和镭-223）已被证明可延长化疗后 CRPC 患者的总生存期。靶向雄激素受体途径在 CRPC 的治疗中仍然具有重要作用，醋酸阿比特龙和恩扎鲁胺是最令人兴奋的进展。卡巴他赛现在被认为是转移性 CRPC（mCRPC）患者的标准二线化疗药物。骨靶向治疗是一个活跃的研究领域，地舒单抗是第一个能够显著延迟 CRPC 患者骨转移出现的骨靶向药物，镭-223 是第一个能够改善 mCRPC 患者生存的放射性药物。
